

Gavin B Bart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/539761/publications.pdf>

Version: 2024-02-01

26
papers

1,401
citations

687363

13
h-index

642732

23
g-index

27
all docs

27
docs citations

27
times ranked

1724
citing authors

#	ARTICLE	IF	CITATIONS
1	Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year. <i>Journal of Substance Abuse Treatment</i> , 2022, 133, 108590.	2.8	16
2	A pilot study of the functionality and clinician acceptance of a clinical decision support tool to improve primary care of opioid use disorder. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 37.	2.6	4
3	Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study. <i>Drug and Alcohol Dependence</i> , 2021, 227, 109025.	3.2	3
4	Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report. <i>Addiction Science & Clinical Practice</i> , 2020, 15, 4.	2.6	11
5	Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis. <i>Journal of Substance Abuse Treatment</i> , 2019, 97, 41-46.	2.8	22
6	Commentary on physicians's satisfaction with providing buprenorphine treatment by Knudsen et al.. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 33.	2.6	2
7	A Quality Framework for Emergency Department Treatment of Opioid Use Disorder. <i>Annals of Emergency Medicine</i> , 2019, 73, 237-247.	0.6	48
8	Author Response to Stoklosa and Haber. <i>Journal of Addiction Medicine</i> , 2018, 12, 167-168.	2.6	0
9	Ethnic differences in psychosocial factors in methadone maintenance: Hmong versus non-Hmong. <i>Journal of Ethnicity in Substance Abuse</i> , 2018, 17, 108-122.	0.9	1
10	Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort. <i>Journal of Addiction Medicine</i> , 2017, 11, 489-493.	2.6	24
11	Ethnic and genetic factors in methadone pharmacokinetics: A population pharmacokinetic study. <i>Drug and Alcohol Dependence</i> , 2014, 145, 185-193.	3.2	40
12	Prescribing controlled substances during a prescription drug epidemic. <i>Neurology: Clinical Practice</i> , 2014, 4, 99-105.	1.6	1
13	Collaborative work between the West and Asia. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S21-S22.	1.9	0
14	Emerging drug problems in Asia. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S19-S20.	1.9	2
15	Collaborative addiction research in the United States and Asia. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S106-S108.	1.9	2
16	Superior methadone treatment outcome in Hmong compared with non-Hmong patients. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 269-275.	2.8	10
17	Maintenance Medication for Opiate Addiction: The Foundation of Recovery. <i>Journal of Addictive Diseases</i> , 2012, 31, 207-225.	1.3	389
18	Promise of extended-release naltrexone is a red herring. <i>Lancet, The</i> , 2011, 378, 663.	13.7	3

#	ARTICLE	IF	CITATIONS
19	CSAT's QT Interval Screening in Methadone Report: Outrageous Fortune or Sea of Troubles?. Journal of Addictive Diseases, 2011, 30, 313-317.	1.3	14
20	Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction, 2008, 103, 681-686.	3.3	14
21	Altered Levels of Basal Cortisol in Healthy Subjects with a 118G Allele in Exon 1 of the Mu Opioid Receptor Gene. Neuropsychopharmacology, 2006, 31, 2313-2317.	5.4	37
22	Increased Attributable Risk Related to a Functional μ -Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden. Neuropsychopharmacology, 2005, 30, 417-422.	5.4	198
23	Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments. Pharmacological Reviews, 2005, 57, 1-26.	16.0	338
24	Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?. Neuropsychopharmacology, 2005, 30, 2254-2262.	5.4	121
25	Suppressed Prolactin Response to Dynorphin A1-13 in Methadone-Maintained Versus Control Subjects. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 581-587.	2.5	49
26	Corticotropin-Releasing Factor Testing Reveals a Dose-Dependent Difference in Methadone Maintained Vs Control Subjects. Neuropsychopharmacology, 2003, 28, 985-994.	5.4	52